Video Lectures
State-of-the-industry video lectures by leading urology experts
Latest Videos

ORLANDO, FL USA (UroToday.com) - During the “Advanced Prostate Cancer II” session, Dr. Matthew Cooperberg presented data from PROCEED, an ongoing Phase 4 registry of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (ST). ST is an immunotherapy that targets prostatic acid phosphatase. While PROCEED is ongoing, baseline demographics and treatment practice patterns were reported. Data from approximately 1 400 patients was included. The majority of patients were Caucasian (87.6%) with a median age of 72 years. Median baseline PSA was 16.1 ng/mL, and 49.9% of patients had Gleason ≥ 8 disease.

auaClose to three-quarters of patients underwent local therapy, the majority with radiation (56.9%) or radical prostatectomy (35.8%). Fifteen percent of patients received prior chemotherapy (12.4% docetaxel). Patients treated in oncology practices more commonly received prior oral anti-androgen (67%) and chemotherapy (19%) compared to patients treated in urology practices (41.7% and 5.9%, respectively). The preliminary data from PROCEED provides a window into current treatment patterns for mCRPC. Dr. Cooperberg concluded that PROCEED will continue to provide useful information for tracking practice patterns and care trends for men with mCRPC prior and subsequent to treatment with ST.

Click HERE to view the poster from this session

Presented by Matthew Cooperberg, MD, MPH at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

University of California, San Francisco USA

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

Clinical Trials
Searchable data base of currently enrolling clinical trials
Calendar
Upcoming urology industry events
June 23-26, 2018 /
2018 CUA Annual Meeting
July 9-12, 2018 / Tan Tock Seng Hospital
Urology Residents' Course Singapore 2018
Journals
Print publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 2 Issue 4

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor